Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Endometrial Cancer

Aliases
Endometrial Adenocarcinoma

239 clinical trials

266 products

36 drugs

1 abstract

Product
TNG260
Product
Pembrolizumab
Clinical trial
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Status: Recruiting, Estimated PCD: 2025-12-31
Product
CPI-0209
Product
CPL304110
Clinical trial
A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-03-15
Clinical trial
Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)
Status: Recruiting, Estimated PCD: 2027-04-27
Product
REGN5668
Product
Cemiplimab
Product
REGN4018
Product
Sarilumab
Product
vudalimab
Product
CT-0508
Clinical trial
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Terminated, Estimated PCD: 2023-06-02
Clinical trial
An Open-Label Study of GV20-0251 in Patients With Advanced and/or Refractory Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-12-15
Clinical trial
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Status: Active (not recruiting), Estimated PCD: 2020-06-29
Product
MDX2001
Clinical trial
An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
Status: Recruiting, Estimated PCD: 2025-10-30
Product
Carboplatin
Clinical trial
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Product
Doxorubicin
Product
NP137
Product
Aromatase Inhibitor
Product
BNT323/DB-1303
Product
Paclitaxel
Product
AO-252
Clinical trial
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-28
Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Fruquintinib
Product
Tislelizumab
Product
FPI-1547
Product
BDC-1001
Product
Nivolumab
Clinical trial
Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
[225Ac]-FPI-1434
Product
FPI-1175
Product
GV20-0251
Clinical trial
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-30
Product
MDNA11
Product
XMT-1660
Clinical trial
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
LY3484356
Product
Abemaciclib
Product
Everolimus
Product
Pertuzumab
Product
PRT3645
Product
Alpelisib
Clinical trial
A Phase 2, Open-Label, Safety Lead-In With Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Product
CYH33
Clinical trial
Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Status: Terminated, Estimated PCD: 2023-02-15
Product
EG-007
Product
Lenvatinib
Product
XmAb®23104
Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Yervoy
Clinical trial
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-08-24
Clinical trial
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation
Status: Recruiting, Estimated PCD: 2025-08-30
Product
NT-112
Clinical trial
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Intravenously as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
T3011
Product
NKT3447
Clinical trial
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
BL-M07D1
Clinical trial
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Niraparib
Product
SYD985
Product
ACR-368
Product
[225Ac]-FPI-1434 Injection
Product
BBI-355
Clinical trial
A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy
Status: Completed, Estimated PCD: 2023-01-26
Product
NC318
Clinical trial
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
Status: Recruiting, Estimated PCD: 2026-07-31
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2023-04-11
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications
Status: Recruiting, Estimated PCD: 2026-09-30
Product
Erlotinib
Product
Futibatinib
Clinical trial
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Status: Recruiting, Estimated PCD: 2025-12-23
Product
Gemcitabine
Product
ADP-A2M4CD8
Product
BLU-222
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-11-30
Product
Ribociclib
Product
Fulvestrant
Product
AZD5363
Clinical trial
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies
Status: Active (not recruiting), Estimated PCD: 2019-04-26
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Status: Recruiting, Estimated PCD: 2024-06-30
Product
PC14586
Product
pembrolizumab
Clinical trial
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Status: Recruiting, Estimated PCD: 2026-03-17
Product
IMGN151
Clinical trial
Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-10-01
Product
Naptumomab estafenatox
Product
Obinutuzumab
Clinical trial
Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance
Status: Recruiting, Estimated PCD: 2025-06-06
Product
Dostarlimab
Drug
Atezolizumab
Product
VLS-1488
Clinical trial
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-05-01
Product
MGC026
Clinical trial
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)
Status: Recruiting, Estimated PCD: 2028-01-10
Product
Sacituzumab tirumotecan
Product
NM32-2668
Clinical trial
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-31
Product
Sacituzumab
Product
TOS-358
Clinical trial
A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Product
COM701
Product
COM701 with Opdivo
Clinical trial
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors.
Status: Active (not recruiting), Estimated PCD: 2024-02-29
Clinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Irinotecan
Product
Lurbinectedin
Clinical trial
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Status: Recruiting, Estimated PCD: 2025-04-30
Product
epacadostat
Product
pemigatinib
Product
INCAGN02390
Clinical trial
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Status: Recruiting, Estimated PCD: 2027-05-04
Product
retifanlimab
Product
INCAGN02385
Product
Naptumomab estafenatox and Durvalumab
Clinical trial
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-01
Product
XmAb541
Clinical trial
A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial Cancer
Status: Withdrawn, Estimated PCD: 2028-04-01
Product
Acasunlimab
Product
PRO1107
Clinical trial
A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-01
Product
PF-06940434
Product
PF-06801591
Clinical trial
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
HS-20089
Product
AZD5305
Product
TORL-1-23
Clinical trial
A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2026-12-15
Clinical trial
Phase II/III Study of the Safety and Efficacy of BAT1308 in Combination With Platinum-containing Chemotherapy for First-line Treatment of Advanced or Recurrent Mismatch Repair Protein-deficient (dMMR) Endometrial Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Product
T- Dxd
Product
Camizestrant
Product
Recombinant humanized anti-PD-1 monoclonal antibody
Product
cemiplimab
Clinical trial
A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
Status: Recruiting, Estimated PCD: 2026-06-21
Product
Dato-DXd
Product
carboplatin
Product
XmAb20717
Clinical trial
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
Status: Recruiting, Estimated PCD: 2024-11-01
Product
BP1001-A
Clinical trial
A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Status: Completed, Estimated PCD: 2020-09-09
Product
DKN-01
Clinical trial
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
TPST-1495
Clinical trial
A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies
Status: Completed, Estimated PCD: 2017-01-24
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Selinexor
Product
Envafolimab+Lenvatinib
Clinical trial
An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-31
Product
Envafolimab
Product
GEN1047
Clinical trial
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
NC410
Product
Afuresertib
Clinical trial
A Phase I/II Dose-Escalation and Efficacy/Safety Study of Afuresertib Plus Sintilimab Plus Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Treatment
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Docetaxel
Clinical trial
Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Aldesleukin
Product
Pemigatinib
Clinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-06-01
Product
Neoantigen specific TCR-T cell
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
Status: Terminated, Estimated PCD: 2021-12-17
Product
Cisplatin
Product
Nab paclitaxel
Product
Sintilimab
Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Status: Completed, Estimated PCD: 2023-02-16
Product
XmAb®22841
Clinical trial
A Phase I/II, Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Endometrial Cancer or Squamous NSCLC
Status: Completed, Estimated PCD: 2020-06-01
Product
Retifanlimab
Product
ABTL0812
Product
Botensilimab
Product
Balstilimab
Product
SKB264
Clinical trial
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Evaluating the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for First-line Treatment of Patient With Advanced Endometrial Cancer or Sarcoma of Uterus: a Multi-center, Open-label, Randomized Controlled, Phase II Clinical Trial.
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Anlotinib
Product
Gemcitabine Hydrochloride
Clinical trial
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Status:
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Status: Recruiting, Estimated PCD: 2024-08-01
Product
STRO-002
Product
TQB2450
Clinical trial
A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-01-25
Clinical trial
A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab vs. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Toripalimab
Clinical trial
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
AI-061
Product
Doxorubicin Hydrochloride
Product
ILB-2109
Product
RGX-104
Clinical trial
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies
Status: Recruiting, Estimated PCD: 2023-12-01
Product
Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Product
Ipilimumab
Product
Pemetrexed
Clinical trial
A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-02-06
Product
ART0380
Clinical trial
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Tc 99m EC20
Clinical trial
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-07-27
Clinical trial
A MULTI-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FOLATESCAN (TECHNETIUM Tc 99m EC20) IN PATIENTS WITH SUSPECTED OVARIAN CARCINOMA OR RECURRENT ENDOMETRIAL CARCINOMA
Status: Completed
Product
Tinostamustine
Product
AMXT1501
Product
DFMO
Clinical trial
A Multi-center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
Status: , Estimated PCD: 2004-08-01
Product
cabozantinib
Product
atezolizumab
Product
CK-301
Clinical trial
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Status: Recruiting, Estimated PCD: 2021-11-18
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2022-11-28
Product
Oxaliplatin
Product
5-Fluorouracil
Product
INCB001158
Product
Leucovorin
Clinical trial
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-07-01
Clinical trial
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Status: Completed, Estimated PCD: 2021-08-18
Product
Etrumadenant
Product
Zimberelimab
Product
AMT-151
Product
AL3818
Clinical trial
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
Pegylated Liposomal Doxorubicin
Product
Topotecan
Clinical trial
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
CPI-006
Clinical trial
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Status: Completed, Estimated PCD: 2022-12-28
Product
CPI-006 + Pembrolizumab
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Status: Completed, Estimated PCD: 2021-11-12
Product
Enapotamab vedotin
Product
TH1902
Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-06-30
Product
AZD8205
Drug
Tiragolumab
Clinical trial
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2019-11-01
Product
AZD2014
Product
Anastrozole
Clinical trial
A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging
Status: Terminated, Estimated PCD: 2019-10-01
Clinical trial
Uterine Cancer Risk Reducing Strategies in Postmenopausal Women
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Provera
Clinical trial
The Molecular and the Clinical Effects of Preoperative Niraparib in Patients With High-grade Endometrial Cancer: Phase 0 Exploratory Trial
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer, a Phase II Efficacy Study
Status: Recruiting, Estimated PCD: 2027-12-30
Clinical trial
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Product
LY2880070
Drug
Gemcitabine
Clinical trial
A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer
Status: Recruiting, Estimated PCD: 2026-04-30
Product
ZEN-3694
Clinical trial
Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Talazoparib
Clinical trial
A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2028-08-31
Product
Letrozole
Clinical trial
A Phase II Evaluation of Pembrolizumab, a Humanized Antibody Against PD-1, in the Treatment of Persistent or Recurrent Hypermutated/Ultramutated Endometrial Cancer Identified by Next Generation Sequencing (NGS) and Comprehensive Genomic Profiling (CGP)
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Status: Terminated, Estimated PCD: 2020-09-09
Drug
ONC201
Product
Tuvusertib
Clinical trial
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Drug
T-VEC
Clinical trial
18-fluorofuranylnorprogesterone (FFNP) Positron Emission Tomography-Magnetic Resonance Imaging (PET/MRI) as a Potential Biomarker of Response to Progesterone Therapy in Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrial Cancer (EC)
Status: Recruiting, Estimated PCD: 2025-06-28
Product
18F-fluorofuranylnorprogesterone
Clinical trial
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Recruiting, Estimated PCD: 2028-06-30
Drug
Tegavivint
Clinical trial
Multicenter Double Blind Randomized Phase II Trial of Olaparib vs Placebo as Maintenance Therapy in Platinum-sensitive Advanced Endometrial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-05-22
Product
Olaparib
Product
Placebo
Clinical trial
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Status: Active (not recruiting), Estimated PCD: 2026-10-29
Product
Copanlisib
Drug
fulvestrant
Clinical trial
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamide
Clinical trial
Iron Prehabilitation and Perioperative Infectious Diseases of Endometrial Cancer Patients
Status: Completed, Estimated PCD: 2024-01-01
Product
Ferrous Gluconate
Product
Cabozantinib
Drug
Abraxane
Clinical trial
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
Status: Recruiting, Estimated PCD: 2026-03-01
Drug
AN0025
Drug
Cisplatin
Clinical trial
A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Status: Completed, Estimated PCD: 2020-05-12
Product
Rucaparib
Clinical trial
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Neoantigen Peptide Vaccine
Clinical trial
Canadian Multi-arm Multi-stage Randomized Controlled Trial Assessing Front Line and Maintenance Treatment in Serous or p53 Mutant Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-09-12
Clinical trial
Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-01-15
Clinical trial
Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Bevacizumab
Clinical trial
A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
4FMFES Positron Emission Tomography (PET) for Detection of Newly-diagnosed ER+ Endometrial and Ovarian Cancers
Status: Completed, Estimated PCD: 2023-08-31
Product
Loperamide
Product
hyoscine-n-butylbromide
Clinical trial
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Cobimetinib
Product
Pelcitoclax
Clinical trial
An Exploratory Study: Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients
Status: Completed, Estimated PCD: 2021-03-09
Product
Dendritic Cells
Clinical trial
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
Status: Completed, Estimated PCD: 2024-04-01
Clinical trial
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
Status: Completed, Estimated PCD: 2018-08-17
Clinical trial
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for Mismatch Repair Proficient (pMMR) Recurrent/Unresectable Endometrial Carcinoma
Status: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-05-29
Clinical trial
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Status: Completed, Estimated PCD: 2021-11-12
Clinical trial
MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Biomarker Study of the Wee1 Inhibitor Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
Status: Not yet recruiting, Estimated PCD: 2026-01-31
Product
Azenosertib
Clinical trial
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
Status: Terminated, Estimated PCD: 2023-10-23
Clinical trial
A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer, Avelumab / Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
Avelumab
Product
Axitinib
Clinical trial
Phase II Trial of Vaginal Cuff Brachytherapy Followed by Adjuvant Chemotherapy With Carboplatin and Dose Dense Paclitaxel in Patients With High-Risk Endometrial Cancer
Status: Completed, Estimated PCD: 2019-12-13
Clinical trial
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
Status: Recruiting, Estimated PCD: 2025-08-01
Drug
Navtemadlin
Product
Navtemadlin
Clinical trial
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
Status: Recruiting, Estimated PCD: 2026-05-25
Clinical trial
A Multicenter, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib in Combination With Pembrolizumab in Black Participants With Mismatch Repair-Proficient Recurrent Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-07-31
Product
Durvalumab
Clinical trial
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia.
Status: Recruiting, Estimated PCD: 2024-11-30
Product
Extended Release Metformin
Product
Megestrol
Clinical trial
A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma
Status: Completed, Estimated PCD: 2022-12-30
Product
Tremelimumab
Clinical trial
Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR) - Pilot Study
Status: Recruiting, Estimated PCD: 2024-11-01
Product
68GaNOTA-Anti-HER2
Clinical trial
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2017-11-10
Product
Veliparib
Clinical trial
SENtinel Lymph Node Mapping With GAllium-68-tilmanocept PET/CT in High/High-intermediate Risk Endometrial Cancer: a Pilot Study
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Gallium-68-tilmanocept
Clinical trial
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE)
Status: Not yet recruiting, Estimated PCD: 2028-09-01
Product
Mounjaro
Product
Mirena
Clinical trial
Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Placebos
Clinical trial
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-11
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-07
Product
XB002
Clinical trial
A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Cabo + Dostarlimab
Clinical trial
Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study
Status: Not yet recruiting, Estimated PCD: 2026-09-30
Product
Anticoagulant
Clinical trial
Trial of Maintenance With Niraparib in Patients With Stage III, Stage IV or Platinum-sensitive Recurrent Uterine Serous Carcinoma
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
PRO1184
Clinical trial
Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Product
Ruxolitinib
Product
Technetium Tc-99m Sodium Pertechnetate
Clinical trial
Phase II Study of Concurrent and Sequential Carboplatin and Paclitaxel With Adjuvant Radiotherapy for High Risk Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Carboplatin + Paclitaxel
Clinical trial
Concurrent Use of Lymphoseek and Indocyanine Green for Sentinel Lymph Node Detection in Endometrial Cancer - a Prospective Study
Status: Terminated, Estimated PCD: 2021-06-10
Product
Lymphoseek
Product
Indocyanine Green
Clinical trial
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Sacituzumab Govitecan
Clinical trial
A Phase II Study of Letrozole and RAD001 (Everolimus) in Patients With Advanced or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2028-04-30
Product
RAD001
Clinical trial
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Product
Paclitaxel/epirubcin/carboplatin
Product
Paclitaxel/carboplatin
Clinical trial
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Status: Recruiting, Estimated PCD: 2027-01-31
Drug
mFOLFOX6
Clinical trial
Adjuvant Checkpoint Blockade Plus Radiation In Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSI-H) Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Status: Recruiting, Estimated PCD: 2030-07-01
Product
Neratinib
Product
Nilotinib
Clinical trial
A Phase I Study of PD-1 Inhibition With TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Product
TSR-042
Clinical trial
A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2)
Status: Completed, Estimated PCD: 2024-03-08
Product
ZW25
Clinical trial
A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer
Status: Recruiting, Estimated PCD: 2024-10-01
Product
IMGN853
Product
Panitumumab
Product
Selumetinib
Product
Sotorasib
Clinical trial
A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer
Status: Completed, Estimated PCD: 2015-01-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)
Status: Recruiting, Estimated PCD: 2027-03-09
Product
favezelimab/pembrolizumab
Drug
pembrolizumab
Drug
lenvatinib
Clinical trial
Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
Status: Completed, Estimated PCD: 2023-03-30
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
Adavosertib
Clinical trial
A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056)
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
BMS- 986205
Clinical trial
Next Generation Precision Imaging for Cancer Immunotherapy: Dynamic Nuclear Polarization and Metabolomics Study
Status: Not yet recruiting, Estimated PCD: 2026-07-31
Product
Hyperpolarized 13C-Pyruvate
Clinical trial
A Phase Ib Trial of Vaginal Cuff Brachytherapy + Pembrolizumab (MK3475) Followed by 3 Cycles of Dose Dense Paclitaxel/q 21 Day Carboplatin + Pembrolizumab (MK3475) in High Intermediate Risk Endometrial Cancer
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Binimetinib
Clinical trial
Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Status: Completed, Estimated PCD: 2023-10-12
Drug
Metformin
Product
Capivasertib
Clinical trial
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2026-08-19
Product
Rilvegostomig
Product
Prednisone
Clinical trial
The "Upproach" Approach: A Phase 2 Study Of Upfront Intensity Modulated Proton Beam Therapy (Impt) And Concurrent Chemotherapy For Post-Operative Treatment In Loco-Regionally Advanced Endometrial Cancer
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Product
BG-68501
Drug
Alpelisib
Clinical trial
A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma
Status: Completed, Estimated PCD: 2004-09-18
Product
perifosine
Clinical trial
A Phase II, Single Arm Study of Atezolizumab + Bevacizumab in Women With Advanced, Recurrent or Persistent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase II Study of Ridaforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer
Status: Completed, Estimated PCD: 2012-03-19
Product
ridaforolimus
Product
Gene Expression Analysis
Clinical trial
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma: Two Single-arm, Prospective and Open-label Clinical Study
Status: Recruiting, Estimated PCD: 2024-02-28
Product
Megestrol Acetate
Clinical trial
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-05-09
Product
De-TIL-0255
Clinical trial
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Status: Completed, Estimated PCD: 2022-06-30
Product
Carboplatin/Paclitaxel
Drug
Trastuzumab
Clinical trial
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2015-01-31
Product
Ixabepilone
Clinical trial
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Fosifloxuridine
Drug
Docetaxel
Clinical trial
A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2026-12-31
Clinical trial
Endometrial Cancer Recurrence in Patients Taking Metformin
Status: Active (not recruiting), Estimated PCD: 2023-02-27
Product
Metformin
Clinical trial
Pilot Phase II Study of the PI3K Inhibitor Copanlisib in Combination With a Ketogenic Diet in the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma or Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
HMBD-001
Clinical trial
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Product
ETX-19477
Clinical trial
An Open-label, Single Arm, Prospective, Multi-center, Tandem Two Stage Designed, Phase II Study to Evaluate the Efficacy of Fulvestrant in Women With Recurrent/Metastatic Estrogen Receptor Positive Gynecological Malignancies
Status: Completed, Estimated PCD: 2022-04-01
Clinical trial
ENGOT-EN3-NSGO/PALEO: A Randomized, Double-blind, Placebo-controlled, Phase II Trial of Palbociclib in Combination With Letrozole Versus Placebo in Combination With Letrozole for Patients With Estrogen Receptor Positive Advanced or Recurrent Endometrial Cancer.
Status: Completed, Estimated PCD: 2020-12-15
Product
Palbociclib/placebo
Drug
Tucidinostat
Clinical trial
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging
Status: Completed, Estimated PCD: 2016-11-16
Product
Isosulfan Blue
Clinical trial
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Status: Withdrawn, Estimated PCD: 2021-11-17
Product
Vic-trastuzumab duocarmazine
Clinical trial
Study of Pembrolizumab Combined With Ataluren In Patients With Metastatic pMMR and dMMR Colorectal Adenocarcinomas or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
Status: Recruiting, Estimated PCD: 2023-06-01
Product
Ataluren + Pembrolizumab
Clinical trial
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Cediranib
Drug
olaparib
Clinical trial
Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis
Status: Recruiting, Estimated PCD: 2026-11-01
Product
Descriptive and analytical
Clinical trial
A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2025-12-30
Product
Vistusertib
Clinical trial
First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
PHN-010
Clinical trial
A Randomized, Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced or Recurrent Endometrial Cancer
Status: Not yet recruiting, Estimated PCD: 2028-09-01
Product
Sapanisertib
Product
Serabelisib
Clinical trial
An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-01-10
Clinical trial
A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Drug
Ceralasertib
Clinical trial
Phase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (EC)
Status: , Estimated PCD: 2026-12-31
Product
AdHER2DC
Drug
N-803
Clinical trial
A Phase II Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
Status: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy With Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3
Status: Active (not recruiting), Estimated PCD: 2018-11-29
Product
cisplatin
Drug
carboplatin
Clinical trial
A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-10-01
Product
Atezolizumab
Product
Ipatasertib
Product
Trastuzumab emtansine
Drug
Inavolisib
Product
Giredestrant
Clinical trial
Optimal Dosing of Oral Anticancer Drugs in Older Adults With Cancer: a Randomized Pilot Study.
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Product
Sunitinib
Product
Palbociclib
Product
Pazopanib
Clinical trial
A Prospective Study of Early Detection of Endometrial Cancer Using Plasma Cell-free DNA Fragmentomics
Status: Recruiting, Estimated PCD: 2024-01-31
Product
Low-depth whole-genome sequencing technology
Clinical trial
Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing: A-TRAIN
Status: Recruiting, Estimated PCD: 2024-12-31
Product
NGS analysis of ctDNA
Drug
Alpelisib
Clinical trial
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
APL-5125
Drug
fluorouracil
Clinical trial
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma: A Multi-center, Open-label, Prospective Clinical Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
IPH5301
Clinical trial
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
Efficacy and Safety of Cadonilimab (AK104) Plus Chemotherapy in the Treatment of Recurrent or Advanced Endometrial Cancer: a Multicenter, Prospective Phase II Trial
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Drug
Cadonilimab
Product
Afatinib
Clinical trial
Phase Ib IIT of Heat Shock Protein 90 Inhibitor TAS-116 Combined With Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Advanced Breast Cancer Progressing on Palbociclib & Treatment-refractory Solid Tumors With Retinoblastoma Deficiency
Status: Recruiting, Estimated PCD: 2024-08-01
Product
TAS-116
Product
Datopotamab deruxtecan
Drug
Saruparib
Drug
UTD1
Product
Volrustomig
Clinical trial
ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer
Status: Completed, Estimated PCD: 2021-10-20
Product
Nintedanib
Clinical trial
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma: A Retrospective Study
Status: Completed, Estimated PCD: 2022-11-22
Clinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)
Status: Recruiting, Estimated PCD: 2026-03-31
Product
Trastuzumab Deruxtecan
Clinical trial
Phase 2 Multicenter Study to Assess the Safety and Efficacy of BKM120 as Monotherapy in Treatment of Initial or Recurrent Metastatic Endometrial Cancer After 1st Line Therapy in Patients Who Cannot Undergo Local Surgery and/or Radiotherapy
Status: Completed, Estimated PCD: 2014-10-01
Product
BKM120
Clinical trial
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2022-12-16
Clinical trial
Optimising Cardiovascular Health in Endometrial Cancer Survivors
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Product
Cardiovascular Agents
Clinical trial
A Phase II Trial of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Status: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy
Status: Terminated, Estimated PCD: 2021-08-18
Product
Nicotinamide Riboside
Product
Temsirolimus
Clinical trial
A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic Cancer
Status: Terminated, Estimated PCD: 2022-07-15
Clinical trial
Phase 1 2 Study of Individualized Bone Marrow Sparing Image Guided Radiotherapy Incorporating Novel Use of Granulocyte Colony Stimulating Factor and FDG PET Imaging
Status: Recruiting, Estimated PCD: 2025-05-01
Drug
GCSF
Clinical trial
A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma
Status: Withdrawn, Estimated PCD: 2022-08-30
Product
Paclitaxel/Carboplatin
Clinical trial
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Post PD1 Exposure: Phase II Trial
Status: Withdrawn, Estimated PCD: 2025-07-01
Drug
Sitravatinib
Clinical trial
Phase 2, Randomized, Trial of Maintenance Letrozole/Abemaciclib vs Pembrolizumab After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wild-type Endometrial Cancer
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
Single-Arm, Open-Label, Phase II Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Status: Completed, Estimated PCD: 2022-03-23
Product
LY3023414
Clinical trial
A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-03-01
Drug
nab-sirolimus
Clinical trial
Efficacy and Safety of Trilaciclib in Myeloprotection During Chemotherapy for Advanced/Recurrent Malignant Solid Tumors - A Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-09-30
Product
Trilaciclib
Clinical trial
Phase I-II Study to Evaluate the Safety, Tolerability, and Efficacy of Lurbinectedin and Dostarlimab in Patients With Advanced/Recurrent Endometrial Cancer With Disease Progression Following Previous Platinum Chemotherapy Therapy
Status: Not yet recruiting, Estimated PCD: 2024-05-01
Drug
Lurbinectedin
Clinical trial
Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Status: Recruiting, Estimated PCD: 2026-04-01
Drug
Carboplatin-Paclitaxel
Abstract
https://www.abstractsonline.com/pp8/#!/20272/presentation/11425
Product
Mirvetuximab Soravtansine
Clinical trial
A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.
Status: Not yet recruiting, Estimated PCD: 2028-05-01
Product
Lifileucel